Myo vs. Myofascial Injection for Myofascial Trigger Points
Myofascial Pain, Myofascial Trigger Point Pain, Trigger Point Pain, Myofascial
About this trial
This is an interventional treatment trial for Myofascial Pain focused on measuring usg-guided trigger point injections, myofascial pain, myofascial trigger point, fascial hydrodilatation
Eligibility Criteria
Inclusion Criteria: Pain in the upper back area Detection of active trigger point in upper back muscles (trapezius, levator scapula, rhomboids, supraspinatus and infraspinatus) Presence of at least two of the three criteria recommended for the diagnosis of trigger point: Taut band Hypersensitive point Referred pain Pain VAS score ≥ 4 Between the ages of 18-65 - Exclusion Criteria: Using analgesics or anti-inflammatory medicines. Having received physical therapy for the same symptoms in the past 3 months Serious psychiatric illness Presence of malignancy or infection Coagulation disorder Pregnancy History of operation in the relevant region Presence of fibromyalgia syndrome History of allergy to local anesthetics -
Sites / Locations
- Izmir Bozyaka Education and Research Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Research arm
Control arm
After the myofascial trigger points are determined by ultrasonography (HI VISION Preirus; Hitachi Aloka Medical, Ltd., Tokyo, Japan), injections will be given to the myofascial layers from the deep to the superficial. First, the local anesthetic solution will be injected to create a separation in the intermuscle (epimysial) fascia. The injectable will then be infiltrated into the intermuscular hypoechoic nodule. Then, the deep fascia will be infiltrated layer by layer. Finally, the procedure will be completed by infiltrating the superficial fascia.
Patients in the control group will be injected with the same amount of local anesthetic solution under ultrasound guidance to intramuscular hypoechoic nodules detected by ultrasonography (HI VISION Preirus; Hitachi Aloka Medical, Ltd., Tokyo, Japan).